2269:HKG
WuXi Biologics (Cayman) Inc
HK$48.20
arrow_downward
-0.90%(-0.44) 1D
Oct 16, 4:08:14 PM GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2269...
Open
HK$49.98
High
HK$50.85
Low
HK$45.82
Mkt. cap
198.43B
Avg. vol.
30.42M
Volume
55.18M
P/E ratio
34.48
52-wk high
HK$58.00
52-wk low
HK$28.48
EPS
HK$1.40
Shares outstanding
1.23B
No. of employees
15K
Open
HK$49.98
High
HK$50.85
Low
HK$45.82
Mkt. cap
198.43B
Avg. vol.
30.42M
Volume
55.18M
P/E ratio
34.48
52-wk high
HK$58.00
52-wk low
HK$28.48
EPS
HK$1.40
Shares outstanding
1.23B
No. of employees
15K
News stories
From web sources and news partners
FOREX.com
·
31 minutes ago
S&P 500, Nasdaq, Dow and Russell 2000 For the Week Ahead
Yahoo Finance
·
4 hours ago
Iambic Therapeutics (IAM) Joins The Nasdaq Composite, Is The Stock Already Pricey?
디지털투데이
·
5 hours ago
Bitcoin could fall to $10,000 if S&P 500 drops 20 percent - Bloomberg
CryptoRank
·
11 hours ago
The S&P 500 Is Near Record Highs: But Most Stocks Are Already in a Bear Market
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About WuXi Biologics (Cayman) Inc